Stay updated on Nivolumab Combinations in EGFR/ALK NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combinations in EGFR/ALK NSCLC Clinical Trial page.

Latest updates to the Nivolumab Combinations in EGFR/ALK NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.5.0 added; Lung cancer and related topics (MedlinePlus Genetics) removed; Revision: v3.4.3 removed.SummaryDifference0.2%

- Check22 days agoChange DetectedLung cancer and MedlinePlus Genetics were added as related topics on the study page.SummaryDifference0.1%

- Check29 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision: v3.4.2 added. Lung cancer and related topics (MedlinePlus Genetics) and Revision: v3.4.1 were removed.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now shows Revision: v3.4.1, replacing Revision: v3.4.0. This is a minor update to the revision metadata.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded related topics in the Related topics section: Lung cancer and MedlinePlus Genetics; no changes to the core study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Combinations in EGFR/ALK NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combinations in EGFR/ALK NSCLC Clinical Trial page.